- Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
- GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate
- Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer
- Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting
- Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders
No comments to show.